Trial Profile
Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PORTIA
- Sponsors Novartis Pharmaceuticals
- 18 Feb 2022 Status changed from discontinued to completed.
- 02 Dec 2021 Status changed from completed to discontinued.
- 28 Sep 2021 Status changed from active, no longer recruiting to completed.